Steroid 5 α-reductase inhibitors targeting BPH and prostate cancer
- 31 May 2011
- journal article
- review article
- Published by Elsevier BV in The Journal of Steroid Biochemistry and Molecular Biology
- Vol. 125 (1-2), 32-38
- https://doi.org/10.1016/j.jsbmb.2010.09.003
Abstract
No abstract availableKeywords
This publication has 51 references indexed in Scilit:
- SRD5A3 Is Required for Converting Polyprenol to Dolichol and Is Mutated in a Congenital Glycosylation DisorderCell, 2010
- Update on chemoprevention for prostate cancerCurrent Opinion in Urology, 2010
- Variability in the Androgen Response of Prostate Epithelium to 5α-Reductase Inhibition: Implications for Prostate Cancer ChemopreventionCancer Research, 2010
- Current status of 5α-reductase inhibitors in the management of lower urinary tract symptoms and BPHWorld Journal of Urology, 2009
- Effects of the 5 alpha‐reductase inhibitor dutasteride on gene expression in prostate cancer xenograftsThe Prostate, 2009
- Phase II Study of Dutasteride for Recurrent Prostate Cancer During Androgen Deprivation TherapyJournal of Urology, 2009
- Finasteride Does Not Increase the Risk of High-Grade Prostate Cancer: A Bias-Adjusted Modeling ApproachCancer Prevention Research, 2008
- The Rationale for Inhibiting 5α-Reductase Isoenzymes in the Prevention and Treatment of Prostate CancerJournal of Urology, 2008
- Effects of dutasteride on the expression of genes related to androgen metabolism and related pathway in human prostate cancer cell linesInvestigational New Drugs, 2007
- Decreased gene expression of steroid 5 alpha‐reductase 2 in human prostate cancer: Implications for finasteride therapy of prostate carcinomaThe Prostate, 2003